Welcome to our dedicated page for Oramed Pharmaceuticals news (Ticker: ORMP), a resource for investors and traders seeking the latest updates and insights on Oramed Pharmaceuticals stock.
Oramed Pharmaceuticals Inc. (ORMP) generates news at the intersection of clinical-stage drug development, oral delivery technology, and strategic healthcare investments. The company describes itself as a platform technology pioneer in oral delivery solutions for drugs currently delivered via injection, centered on its Protein Oral Delivery (POD™) technology and a refined oral insulin program.
News about Oramed often covers clinical and strategic milestones for its oral insulin and POD™ platform, including updates on trial design, analysis of Phase 2 and Phase 3 data, and plans for U.S.-based clinical studies. Company letters to shareholders and press releases provide context on how Oramed is advancing its oral insulin program independently and how it evaluates high-responder subgroups in its clinical data.
Another major source of headlines is Oramed’s investment and partnership activity across the biomedical and medical technology landscape. Releases have detailed structured financings and royalty arrangements with Scilex Holding Company, a substantial equity investment and strategic collaboration with Alpha Tau Medical Ltd., and positions in companies such as BioXcel Therapeutics Inc. and Pelthos Therapeutics Inc. These updates often discuss repayments, warrant structures, royalty interests, and unrealized gains.
Recent news also highlights transformative corporate transactions, such as the announced transfer of Oramed’s POD™ technology to Lifeward Ltd. in exchange for a significant beneficial ownership interest and participation in a revenue-generating medical robotics business. Additional items include stock repurchase programs, cash dividend declarations, and the adoption of a Rights Agreement involving common stock purchase rights.
Investors and followers of ORMP news can use this page to review Oramed’s press releases, shareholder letters, and transaction announcements in one place, tracking developments in its oral drug delivery platform, strategic investments, and corporate actions over time.
Oramed Pharmaceuticals (Nasdaq: ORMP) has initiated a global Phase 2 trial for its oral insulin capsule, ORMD-0801, targeting Nonalcoholic Steatohepatitis (NASH). The trial will include eight clinical sites across the U.S., EU, and Israel, focusing on efficacy measured via MRI-PDFF over a 12-week dosing period. Prior studies indicated a 30% reduction in liver fat with ORMD-0801, fueling optimism for this trial. CEO Nadav Kidron expressed excitement for the international trial and the potential to provide groundbreaking treatment for NASH.
Oramed Pharmaceuticals has initiated its global Phase 3 trials for the oral insulin capsule, ORMD-0801, aimed at treating type 2 diabetes (T2D). The screening of the first patients took place at U.S. sites in the ORA-D-013-1 trial, part of a broader two-trial program involving 1,125 patients over 6 to 12 months. The primary goal is to assess ORMD-0801's efficacy against a placebo in glycemic control. CEO Nadav Kidron highlighted the significance of this milestone as the first FDA Phase 3 oral insulin trial.
Oramed Pharmaceuticals Inc. (Nasdaq/TASE: ORMP) announced a webinar on November 18, 2020, featuring Nobel Laureate Prof. Avram Hershko and Chief Scientific Officer Dr. Miriam Kidron. This session is part of a series focusing on the company's progress in oral drug delivery systems, especially its oral insulin candidate, ORMD-0801, which is entering Phase 3 trials in the U.S. Oramed aims to transform diabetes treatment with its proprietary Protein Oral Delivery (POD™) technology. Interested investors can register for the webinar via a provided link.
Oramed Pharmaceuticals (Nasdaq: ORMP) will have CEO Nadav Kidron present an overview at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 11:30 AM ET. The company is focused on oral drug delivery systems, aiming to revolutionize diabetes treatment with its lead candidate, ORMD-0801, potentially the first oral insulin capsule. Oramed has completed multiple Phase II trials and is also developing ORMD-0901, an oral GLP-1 analog.
Oramed Pharmaceuticals announced its participation in the AAPS 2020 PharmSci 360 conference, presenting research on its oral insulin candidate, ORMD-0801, for Type 2 diabetes. The presentation, led by Dr. Miriam Kidron, focuses on the glycemic effects of bedtime oral insulin in uncontrolled diabetes patients. Oramed aims to innovate diabetes treatment through its proprietary Protein Oral Delivery (POD™) technology, with ORMD-0801 potentially being the first oral insulin capsule. The company has completed multiple Phase II clinical trials under FDA regulations.
Oramed Pharmaceuticals (NASDAQ: ORMP) announced a webinar titled "The Journey of Oral Insulin: Oramed Story," featuring CEO Nadav Kidron and Premas Biotech's Dr. Prabuddha Kundu on October 28, 2020, at 9:00 am ET. The session highlights the advancements in oral insulin delivery, focusing on Oramed's oral insulin capsule, ORMD-0801, which is entering pivotal Phase 3 trials in the U.S. Established in 2006, Oramed aims to revolutionize diabetes treatment with its oral drug delivery technology.
Oramed Pharmaceuticals has submitted protocols for pivotal Phase 3 studies of its oral insulin candidate, ORMD-0801, to the FDA following guidance from the agency. The two studies aim to evaluate the safety and efficacy of ORMD-0801 in approximately 1,125 patients with type 2 diabetes. The U.S. study, ORA-D-013-1, plans to recruit 675 patients across 75 sites, while ORA-D-013-2 will involve 450 patients across 61 sites. Patient enrollment is expected this quarter, with efficacy data anticipated after a 6-month treatment period.
Oramed Pharmaceuticals (Nasdaq: ORMP) announced its participation in the EASD Annual Meeting, taking place virtually from September 21-25, 2020. Dr. Roy Eldor will present on September 22 at 3:45 p.m. CEST, discussing the glycaemic effects of oral insulin (ORMD-0801) in type 2 diabetes patients. Additionally, Dr. Miriam Kidron will showcase a poster on September 24 at 12:00 p.m. CEST, detailing oral insulin's impact on liver fat in T2DM patients with NASH. Oramed focuses on transforming diabetes treatment with its oral insulin capsule technology.
Summary not available.
Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) announced that CEO Nadav Kidron will present a company overview at the H.C. Wainwright 22nd Annual Global Investment Conference, scheduled for September 14-16, 2020. Kidron's presentation will take place on September 15 at 1:30 PM Eastern. Oramed specializes in oral drug delivery solutions, aiming to transform diabetes treatment with its lead candidate, ORMD-0801, the first oral insulin capsule. The company has completed multiple Phase II clinical trials and is also developing an oral GLP-1 analog capsule, ORMD-0901.